Arthritis medicines and cardiovascular events- "House of coxibs"
Article Abstract:
Physicians, patients and the general public are dealing with confusional state regarding the cardiovascular safety of medicines for arthritis. The National Cancer Institute announced the premature cessation of a trial of celecoxib known as Adenoma Prevention with Celecoxib (APC) due to significant excess of cardiovascular death, myocardial infarction (MI) and stroke on 17 December 2004.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Protein carbamylation links inflammation, smoking, uremia and atherogenesis
Article Abstract:
Studies about the cyanate formation and protein carbamylation, which is believed to promote vascular dysfunction during end-stage renal disease, are presented. The protein carbamylation mechanism is found directly linked to inflammation, smoking, uremia and coronary artery disease pathogenesis.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Kidney disease and cardiovascular risk. Diagnosis of latent tuberculosis infection
- Abstracts: Jeremiah Stamler, MD: Researcher, leader in cardiovascular disease prevention. Is PSA testing still useful?
- Abstracts: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. Effects of rosiglitazone on the risk of myocardial infraction and death from cardiovascular causes
- Abstracts: The role of ACE inhibitor therapy in treating cardiovascular disease. Identifying and managing the complications of diabetes
- Abstracts: Chronic parotitis: diagnosis and treatment. Drug-induced paraparotid fat deposition in patients with HIV: case reports